Risk factors associated with symptoms induced by other anti-VEGF treatments, including multikinase inhibitors and VEGF-targeting monoclonal antibodies, include prolonged administration periods, Asian ethnicity, low baseline glomerular filtration rate (GFR), co-morbidities such as hypertension, diabetes, and hyperlipidemia, prior nephrectomy, calcium channel blocker use, no renin-angiotensin system inhibitor (RASI) use, and baseline proteinuria existence12–18. The gene discussed is VEGFA; the disease is hyperlipidemia.